2023 Advanced Addiction Psychopharmacology Course

Advanced Addiction Psychopharmacology Early Bird $ ends after 10/1/23

**2023 membership dues must be paid in order to qualify for the member rate.

ABPN email [email protected] for the registration code.

Learners who attend this activity will engage in an in-depth educational experience in addiction psychopharmacology and after participating in this course, learners should be able to:

• Use methadone, buprenorphine and injectable OUD pharmacotherapies in clinical practice for the treatment of opioid use disorders.
• Evaluate medication treatments for alcohol use disorders.
• Determine when to use varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorders.
• Review treatment issues related to stimulant use disorder pharmacotherapy.
• Evaluate new evidence for medication treatments for cannabis use disorder.
• Discuss new evidence for inpatient and outpatient medications for the treatment of sedative-hypnotic use disorder.
• List evidence-based options for treating patients using psychedelics to treat substance use disorders.
• Review evidence-based non-pharmacological treatments such as brain stimulation for treatment of patients with primary and co-occurring substance use disorders.

Alcohol Use Disorder Pharmacotherapy
Brain Stimulation
Cannabis Use Disorder Pharmacotherapy
Nicotine Use Disorder Pharmacotherapy
Opioid Use Disorder Pharmacotherapy
Psychedelics/Ketamine
Stimulant Use Disorder Pharmacotherapy
Sedative-Hypnotic Use Disorder Pharmacotherapy

All registrants will be given access to view 9 pre-recorded on-demand lectures prior to live Q&A sessions with faculty on October 21, 2023, and October 22, 2023. These lectures will be released at the end of September and will require approximately 9.5 hours of time.

Dr. Derek Blevins is an Assistant Professor at Columbia University, a research psychiatrist at the New York State Psychiatric Institute, and a psychiatrist in private practice in Manhattan. He completed his psychiatric residency at the University of Virginia, where he served as chief resident, and a combined clinical and NIDA-funded T32 research fellowship in addiction psychiatry at Columbia University. During his residency, he served as junior attending for the treatment resistant depression clinic at UVA, where he gained experience with repetitive transcranial magnetic stimulation (rTMS), which he continued to pursue in clinical research during residency and now as a junior faculty member at Columbia.

Christina A. Brezing, MD is an Assistant Professor of Psychiatry in the Division on Substance Use Disorders at Columbia University Irving Medical Center where she studies medication development for substance use disorders through clinical trials and applications of technology in the assessment and treatment of substance use disorders. She is Principal Investigator of two NIDA-funded grants including a K23 to study novel pharmacotherapy and applications of technology in the treatment of Cannabis Use Disorder and a R21 to study the comparative effectiveness of telehealth for buprenorphine treatment of Opioid Use Disorder at Columbia’s Substance Treatment and Research Services (STARS) program. She was recently awarded the Columbia University Vagelos College of Physicians, Doris Duke Charitable Foundation COVID-19 Fund to Retain Clinical Scientists that will support her research to understand the effects of testosterone replacement therapy on androgen deficiency in men with Opioid Use Disorder receiving early buprenorphine treatment. She was a Columbia Hadar Fellow and has received research support through the Columbia Smither’s Foundation and the Dartmouth Center for Technology and Behavioral Health. She has served as a co-investigator or study physician on dozens of NIDA-funded medication treatment trials for substance use disorders. She is the director of the addiction curriculum for the Columbia psychiatry residency and co-director of the American Academy of Addiction Psychiatry’s Advanced Addiction Psychopharmacology course.

Dr. Brezing attended Duke University for her undergraduate degree in biology with a focus in biochemistry, and completed her medical degree at the University of Florida where she graduated Alpha Omega Alpha and with honors in research. She completed the Howard Hughes Medical Institute-National Institutes of Health (HHMI-NIH) Research Scholars Program studying neuroimaging of impulse control disorders, including pathological gambling, compulsive sexual behavior, and shopping. She completed psychiatry residency at Harvard Medical School-Massachusetts General Hospital and McLean Hospital, where she served as chief resident in addiction, in addition to a National Institute on Drug Abuse (NIDA) funded T32 research fellowship in Addiction Psychiatry at Columbia University and New York State Psychiatric Institute.

Elias Dakwar, MD is an Assistant Professor of Clinical Psychiatry at the Columbia College of Physicians and Surgeons. After completing his residency in psychiatry, he completed a fellowship in Addiction Psychiatry at Columbia, under the mentorship of Frances Levin, MD. He is currently the principal investigator on several studies evaluating the effects of various medications on opioid, cannabis, or cocaine use disorders in both clinical and laboratory settings at the New York State Psychiatric Institute.

He is currently researching novel treatments for addictions with the support of several grants from NIDA and NIAAA. A special focus of his research has been evaluating sub-anesthetic ketamine infusions for cocaine use disorders in both laboratory and clinical settings, as well as investigating ketamine infusions as an adjunct to mindfulness-based treatment, motivational interviewing, and other behavioral frameworks for alcohol, cannabis, and opioid use disorders. He has a more general interest in the impact of non-ordinary experiences, and of the interventions that might occasion them, in psychiatric treatment.

Kevin M. Gray, M.D., is a Professor in the Department of Psychiatry and Behavioral Sciences and serves as Assistant Vice President for Advancing Research Partnerships at the Medical University of South Carolina (MUSC). As a physician-scientist co-leading the MUSC Youth Collaborative, he conducts National Institutes of Health supported clinical research, contributing novel advances to treatments for substance use disorders in adolescents and young adults. Dr. Gray is Principal Investigator of the National Institute on Drug Abuse/American Academy of Child and Adolescent Psychiatry Physician Scientist Program in Substance Use, serves on the Editorial Board of the Journal of the American Academy of Child and Adolescent Psychiatry, and serves on the Executive Committee of the American Academy of Addiction Psychiatry. In addition to clinical, administrative, and research efforts, Dr. Gray is dedicated to education, providing didactic instruction across training programs and mentoring multiple early career faculty and trainees in clinical research.

John J. Mariani, MD is an Associate Professor of Clinical Psychiatry at the Columbia University Vagelos College of Physicians and Surgeons and a Research Psychiatrist at the New York State Psychiatric Institute (NYSPI). Dr. Mariani is the Director of the Substance Treatment and Research Service (STARS) in the Division on Substance Use Disorders at the NYSPI/Columbia University Irving Medical Center. Dr. Mariani attended the New York University School of Medicine, completed a psychiatry residency at the Beth Israel Medical Center/Albert Einstein College of Medicine, and an addiction psychiatry clinical and research fellowship at Columbia University Medical Center and the New York State Psychiatric Institute. He serves on the board of the American Academy of Addiction Psychiatry and is the medical advisor to the Major League Baseball Players Association. Dr. Mariani’s research is focused on the development of novel medication treatments for substance use disorders and related co-occurring psychiatric disorders. He has received grant funding from the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), as well as private foundations. Dr. Mariani has over 50 peer-reviewed scientific publications, in addition to a dozen book chapters on the treatment of substance use disorders.

Larissa Mooney, MD is an Associate Professor in the Department of Psychiatry and Biobehavioral Sciences, Director of the Addiction Psychiatry Division, and Director of the UCLA-VA Addiction Psychiatry Fellowship Program at the University of California, Los Angeles (UCLA). Dr. Mooney was the Section Chief for Substance Use Disorders at the Greater Los Angeles VA from 2015-2021. She is the President-Elect of the American Academy of Addiction Psychiatry (AAAP), a Distinguished Fellow of the American Psychiatric Association (APA), and a fellow of the American Society of Addiction Medicine (ASAM). Dr. Mooney has conducted research at UCLA Integrated Substance Abuse Programs (ISAP) on pharmacological and behavioral treatment interventions for addictive disorders. She is one of two Principal Investigators for the Greater Southern California Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network. She has current NIDA funding to study functional outcomes in cannabis users and treatment interventions for opioid use disorder and stimulant use disorder.

Dr. Rosenthal is Professor and Inaugural Director of Addiction Psychiatry at Renaissance School of Medicine at Stony Brook University. In that role, he oversees the delivery of addiction services for the Stony Brook Health system and is responsible for addiction-related clinical training for medical students, residents and practitioners. Over his career, he has been active in research, education, program development, treatment and public policy related to addiction. Since 2003, he has been the Head of Public Policy at the American Academy of Addiction Psychiatry.

Dr. Rosenthal earned his master’s degree in physiology and pharmacology at Duke University, where he was the recipient of a National Institutes of Health Neurosciences Training Grant Award. He then earned his medical degree at State University of New York Downstate Medical Center and completed his residency in psychiatry at Mount Sinai Hospital, where he served as Chief Resident. After residency, he founded and directed the Addiction Psychiatry program at Beth Israel Medical Center, NY. More recently, he was chair of psychiatry 2001-2014 at the former St. Luke’s Roosevelt Medical Center, NY.

Dr. Rosenthal is a member of numerous professional societies and served as President of both the American Academy of Addiction Psychiatry and the American Association for Technology in Psychiatry. He is a Distinguished Life Fellow of the American Psychiatric Association, and a Distinguished Fellow of the American Academy of Addiction Psychiatry. He has published articles in many professional journals as well as numerous book chapters and books. He is also an Editor of the American Society of Addiction Medicine Principles of Addiction Medicine. In 2008, Dr. Rosenthal was the recipient of the Founders’ Award from the American Academy of Addiction Psychiatry and has been selected for Castle Connolly America’s Top Doctors™ since 2008.

Dr. Sevarino trained in psychiatry in the dual clinical/basic research tract at the Yale University School of Medicine. For six years thereafter, he was PI on NIH grants examining neurobiological mechanisms underlying cocaine dependence, and since then has transitioned to being a clinician-educator who remained active in clinical research as a member of the MIRECC VA Team in studies examining new treatments for substance use disorders. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He is consulting psychiatrist to Gaylord Hospital, Wallingford, a position he previously held from 1999 - 2009. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He was subspecialty certified in Psychosomatic Medicine by the American Board of Psychiatry and Neurology from 2009 - 2019, in Addiction Medicine by the American Board of Addiction Medicine from 2010 - 2020, and currently in Addiction Medicine by the American Board of Preventative Medicine. Dr. Sevarino is President of the American Academy of Addiction Psychiatry (AAAP). He was Course Director for the AAAP Board Review Course in Addictions, which developed into the Addictions and Their Treatment Course, from 2007 - 2015. He currently co-directs AAAP’s Advanced Addiction Psychopharmacology course.

Jill M. Williams, MD, is Professor of Psychiatry and Director of the Division of Addiction Psychiatry at the Rutgers University-Robert Wood Johnson Medical School in New Brunswick. She also holds faculty appointments at the Cancer Institute of New Jersey and the Rutgers Center for Alcohol Studies. The focus of Dr. Williams work has been in addressing tobacco in individuals with mental illness or other addictions through treatment and systems interventions. She is Medical Director for the TCTTAC Program in NYC, in collaboration with Center for Practice Innovation at Columbia University. In 2015 she was the recipient of the Remarkable Achievement Award of the NJ Psychiatric Association. She is past Chair and current member of the APA Council on Addiction Psychiatry.